Publications by authors named "Takahiro Kinami"
Aim: Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first-line therapy for unresectable hepatocellular carcinoma (u-HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have been seen during treatment. Therefore, the relationships of efficacy, safety, and portal hypertension (PH) were analyzed.
View Article and Find Full Text PDFIntroduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival.
Methods: A total of 825 patients with advanced HCC and Child-Pugh A or B received either Sor, Len or Atezo + Bev as first-line systemic therapy.
Article Synopsis
- The study investigates how skeletal muscle changes during treatment with atezolizumab plus bevacizumab (Atezo + Beva) or lenvatinib (Len) relate to prognosis in patients with hepatocellular carcinoma (HCC).
- It found that while the arm skeletal muscle index (SMI) decreased in patients receiving Len, it remained stable in those treated with Atezo + Beva.
- Additionally, factors like arm SMI and extracellular water to total body water ratio (ECW/TBW) were significant indicators of progression-free survival in the Len group.
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new classification system for fatty liver disease. In this study, we investigated the clinical characteristics of patients with MAFLD-hepatocellular carcinoma (HCC) in comparison with those with nonalcoholic fatty liver disease (NAFLD) and considered the validity and challenges of the new criteria.
Methods: This study included 237 untreated non-B, non-C HCC patients with hepatic steatosis.
Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is currently positioned as the first-line therapy for unresectable hepatocellular carcinoma (u-HCC). It may be difficult to decide whether to continue this treatment if radiological response is assessed as stable disease (SD). Therefore, the relationship between radiological response and prognosis was analyzed.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of stereotactic body radiation therapy (SBRT) on 220 patients with hepatocellular carcinoma (HCC) treated at Hiroshima University Hospital from 2008 to 2021.
- Participants had a median overall survival of 52 months and a disease-free survival of 17 months, with a low local tumor recurrence rate of 3.4% over five years.
- Repeated SBRT showed promising results, with a median overall survival of 76 months and minimal severe side effects, indicating good local control of the disease.
Article Synopsis
- Transarterial chemoembolization (TACE) has traditionally been the go-to treatment for intermediate-stage, unresectable hepatocellular carcinoma (u-HCC), but new studies show systemic therapy can be effective for patients considered TACE-refractory or -unsuitable.
- A study involving 140 patients evaluated the effectiveness of the drug lenvatinib, finding median overall survival of 24.4 months and progression-free survival of 9.0 months, suggesting a good response to treatment.
- The research highlights the importance of using systemic therapy in TACE-refractory patients and indicates that combining TACE after initiating lenvatinib can enhance patient outcomes.